newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

- Sharpening focus on the pipeline extends cash runway into second half of 2024; Ended quarter with approximately $166 million in cash - IND submission for CYT-1853 postponed to focus on CYT-0851 and preclinical pipeline Cyteir Therapeutics, Inc.